Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Executive Summary
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
You may also be interested in...
The Talent Crisis: How To Improve Recruitment And Retain Biopharma Employees
Job candidates have the upper hand right now, but recruiters, investors and employers say there are ways to attract, elevate and retain qualified candidates beyond just paying higher salaries.
Finance Watch: 14 Biopharma Companies Raise $1bn From VC, Canadian Government
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.